Migraine News and Research

Latest Migraine News and Research

FDA accepts MAP Pharmaceuticals’ resubmission of NDA for LEVADEX

MAP Pharmaceuticals, Inc. today announced that its New Drug Application (NDA) resubmission for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA).

22 Nov 2012

New AAN book for people with primary and metastatic brain tumors

It is estimated that every 30 minutes, someone is diagnosed with brain cancer. Published in conjunction with the American Academy of Neurology as part of the Neurology Now Books series, NAVIGATING LIFE WITH A BRAIN TUMOR provides readily accessible information and encouragement for the thousands of people living with primary and metastatic brain tumors.

16 Nov 2012

Women with migraines do not appear to experience cognitive decline

Women with migraines did not appear to experience a decline in cognitive ability over time compared to those who didn't have them, according to a nine-year follow up study funded by the National Institutes of Health.

13 Nov 2012

Children with migraine more likely to have below average school performance

Children with migraine are more likely to have below average school performance than kids who do not have headaches, according to new research published in the October 30, 2012, print issue of Neurology-, the medical journal of the American Academy of Neurology.

30 Oct 2012

Neuros Medical honored as most promising startup

Neuros Medical, Inc., a medical device company, was presented the 2012 Gold Electrode Award for Most Promising Startup at the Neurotech Leaders Forum conference in San Francisco. The award is given by Neurotech Reports, and highlights a company in the neuromodulation industry that holds the most promise.

29 Oct 2012

Migraine linked to depression, stress in sub-Saharan Africans

Migraine is significantly associated with stress and unipolar psychiatric symptoms in sub-Saharan African adults, researchers say.

24 Oct 2012

Antidepressant use may increase risk of strokes caused by bleeding in the brain

Research shows that use of popular antidepressants is linked to an increased risk of some strokes caused by bleeding in the brain, but that the risk is low, according to a multi-study analysis published in the October 17, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.

19 Oct 2012

Scientists reveal interaction between the auditory cortex and amygdala

In a study published in the Journal of Neuroscience and funded by the Wellcome Trust, Newcastle University scientists reveal the interaction between the region of the brain that processes sound, the auditory cortex, and the amygdala, which is active in the processing of negative emotions when we hear unpleasant sounds.

15 Oct 2012

Stroke on the rise among young people

New research reveals that stroke may be affecting people at a younger age. The study is published in the October 10, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

11 Oct 2012

Migraine therapy alleviates more than just the headache

Treating the pain associated with migraine can also improve the social and psychologic problems experienced by individuals affected by the condition, findings from a systematic review suggest.

10 Oct 2012

Eating tomatoes associated with reduced risk of stroke

Eating tomatoes and tomato-based foods is associated with a lower risk of stroke, according to new research published in the October 9, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology. Tomatoes are high in the antioxidant lycopene.

9 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

St. Jude Medical’s Eon family of neurostimulators receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.

21 Sep 2012

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting.

19 Sep 2012

Migraine headaches in children linked to behavioral difficulties

Kids who get migraine headaches are much more likely than other children to also have behavioral difficulties, including social and attention issues, and anxiety and depression. The more frequent the headaches, the greater the effect, according to research out now in the journal Cephalagia, published by SAGE.

17 Sep 2012

Silent infarcts prognostic in young stroke patients

Silent ischemic lesions are common and are associated with a high rate of recurrent events in young patients with acute ischemic stroke, report researchers.

12 Sep 2012

Heptares uses StaR technology to solve structure of CRF-1 receptor

Heptares Therapeutics today announces that it has used its StaR technology to solve entirely in-house the first structure of a Family B sub-class G protein-coupled receptor (GPCR).

10 Sep 2012

Predictors for pain after breast cancer surgery unveiled

Researchers have identified that chronic preoperative pain, axillary surgery, and psychologic robustness significantly predict acute pain outcomes after breast cancer surgery.

5 Sep 2012

People with normal blood sugar range may be at increased risk of brain shrinkage

People whose blood sugar is on the high end of the normal range may be at greater risk of brain shrinkage that occurs with aging and diseases such as dementia, according to new research published in the September 4, 2012, print issue of Neurology-, the medical journal of the American Academy of Neurology.

4 Sep 2012

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

28 Aug 2012